Literature DB >> 25455413

A combination of preoperative CT findings and postoperative serum CEA levels improves recurrence prediction for stage I lung adenocarcinoma.

Motohiko Yamazaki1, Hiroyuki Ishikawa2, Ryosuke Kunii3, Akiko Tasaki2, Suguru Sato2, Yohei Ikeda2, Norihiko Yoshimura2, Takehisa Hashimoto4, Masanori Tsuchida4, Hidefumi Aoyama2.   

Abstract

OBJECTIVES: To assess the prognostic value of combined evaluation of preoperative CT findings and pre/postoperative serum carcinoembryonic antigen (CEA) levels for pathological stage I lung adenocarcinoma.
METHODS: This retrospective study included 250 consecutive patients who underwent complete resection for ≤ 3-cm pathological stage I (T1-2aN0M0) adenocarcinomas (132 men, 118 women; mean age, 67.8 years). Radiologists evaluated following CT findings: maximum tumor diameter, percentage of solid component (%solid), air bronchogram, spiculation, adjacency of bullae or interstitial pneumonia (IP) around the tumor, notch, and pleural indent. These CT findings, pre/postoperative CEA levels, age, gender, and Brinkman index were assessed by Cox proportional hazards model to determine the best prognostic model. Prognostic accuracy was examined using the area under the receiver operating characteristic curve (AUC).
RESULTS: Median follow-up period was 73.2 months. In multivariate analysis, high %solid, adjacency of bullae or IP around the tumor, and high postoperative CEA levels comprised the best combination for predicting recurrence (P<0.05). A combination of these three findings had a greater accuracy in predicting 5-year disease-free survival than did %solid alone (AUC=0.853 versus 0.792; P=0.023), with a sensitivity of 85.7% and a specificity of 74.3% at the optimal threshold. The best cut-off values of %solid and postoperative CEA levels for predicting high-risk patients were ≥ 48% and ≥ 3.7 ng/mL, respectively.
CONCLUSION: Compared to %solid alone, combined evaluation of %solid, adjacency of bullae or IP change around the tumor, and postoperative CEA levels improves recurrence prediction for stage I lung adenocarcinoma.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chest CT imaging; Lung adenocarcinoma; Lung cancer; Prognosis; Serum CEA levels

Mesh:

Substances:

Year:  2014        PMID: 25455413     DOI: 10.1016/j.ejrad.2014.10.009

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Use of deep learning to predict postoperative recurrence of lung adenocarcinoma from preoperative CT.

Authors:  Yuki Sasaki; Yohan Kondo; Tadashi Aoki; Naoya Koizumi; Toshiro Ozaki; Hiroshi Seki
Journal:  Int J Comput Assist Radiol Surg       Date:  2022-06-28       Impact factor: 3.421

2.  Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.

Authors:  Shuta Ohara; Kenichi Suda; Kazuko Sakai; Masaya Nishino; Masato Chiba; Masaki Shimoji; Toshiki Takemoto; Toshio Fujino; Takamasa Koga; Akira Hamada; Junichi Soh; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-10

3.  The relationship between tumor markers and pulmonary embolism in lung cancer.

Authors:  Wei Xiong; Yunfeng Zhao; Mei Xu; Jian Guo; Bigyan Pudasaini; Xueling Wu; Jinming Liu
Journal:  Oncotarget       Date:  2017-06-20

Review 4.  [Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer].

Authors:  Bo Liu; Fengxia Ding; Shuangqiang Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-06

5.  A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm.

Authors:  Wang-Yu Zhu; Ke-Xin Fang; Jian-Ying He; Ri Cui; Yong-Kui Zhang; Han-Bo Le
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

6.  Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response.

Authors:  Zhe Wang; Minghuan Li; Yong Huang; Li Ma; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2018-05-04       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.